fmc-376
frontier medicines
['fmc-376']
frontier medicines presents new preclinical data on its development candidate, fmc-376, a dual krasg12c inhibitor, at the 2023 aacr annual meeting 
We provide a complete array of research services as required for Investigational New Drug Applications (IND).